Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/02/2005WO2005048923A2 Extended release venlafaxine formulation
06/02/2005WO2005048922A2 Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors
06/02/2005WO2005048916A2 Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
06/02/2005WO2005048912A2 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
06/02/2005WO2005048810A2 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
06/02/2005WO2005048742A1 Sucrose acetate isobutyrate formulation
06/02/2005WO2005048719A1 Polyphenol-containing stem and vine extracts and methods of use
06/02/2005WO2005048715A2 Organophosphoric compounds and use thereof
06/02/2005WO2005048709A1 Use of panthenol in teat dip/spray preparations
06/02/2005WO2005041889A3 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
06/02/2005WO2005037197A3 Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
06/02/2005WO2005035528A3 Triazole derivatives as antibacterial agents
06/02/2005WO2005035491A3 PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
06/02/2005WO2005034979A3 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
06/02/2005WO2005034954A3 Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
06/02/2005WO2005034929A9 Tissue remodeling and vascularization
06/02/2005WO2005034927A3 Aerosol formulation comprising formoterol in suspension
06/02/2005WO2005034868A3 Methods for treating igf1r-inhibitor induced hyperglycemia
06/02/2005WO2005032478A3 Treatment for diabetic microvascular and macrovascular complications
06/02/2005WO2005032470A3 Compositions and methods for treating burns
06/02/2005WO2005030792A3 Quinoline potassium channel inhibitors
06/02/2005WO2005030332A3 Use of galanthamine and the derivatives thereof in the production of medicaments
06/02/2005WO2005030215A3 Therapeutic treatment
06/02/2005WO2005030184A3 Therapeutic beta aminoacids
06/02/2005WO2005028480A3 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
06/02/2005WO2005028474A3 Pyrazoloquinoline derivatives as chk-1 inhibitors
06/02/2005WO2005027823A3 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
06/02/2005WO2005023806A3 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
06/02/2005WO2005023794A3 Compound libraries of 4-carboxamidopiperidine derivatives
06/02/2005WO2005023270A3 Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
06/02/2005WO2005021504A3 New crystalline forms of carvedilol
06/02/2005WO2005020975A3 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
06/02/2005WO2005019220A9 Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
06/02/2005WO2005018577A3 11-deoxy-6,9-ether erythromycin compounds
06/02/2005WO2005018565A3 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
06/02/2005WO2005016958A3 Compounds for treating tumors
06/02/2005WO2005016879A3 Cyclic pyrazinoylguanidine sodium channel blockers
06/02/2005WO2005016245A3 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
06/02/2005WO2005016225A3 Stable pharmaceutical composition of rabeprazole
06/02/2005WO2005013889A9 Truncated fragments of alpha-synuclein in lewy body disease
06/02/2005WO2005013884A3 Methods for preventing neurological events
06/02/2005WO2005012364A3 Complex matrix for biomedical use
06/02/2005WO2005009961B1 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
06/02/2005WO2005009950A3 Piperidine derivatives as melanocortin-4 receptor agonists
06/02/2005WO2005009349A3 Composition and method for treating neurological disorders
06/02/2005WO2005007845A3 Transgenic cells
06/02/2005WO2005005606A3 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
06/02/2005WO2005005380A3 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
06/02/2005WO2005001041A3 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
06/02/2005WO2005000230A3 Methods of treating hyperproliferative cell disorders
06/02/2005WO2004112762A3 Pharmaceutical formulations of amyloid inhibiting compounds
06/02/2005WO2004105763A3 Use of tyrosine kinase inhibitor to treat diabetes
06/02/2005WO2004105698A3 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
06/02/2005WO2004103986A3 3-desoxyanthocyanidine compounds and uses thereof as antimicrobial agents
06/02/2005WO2004103307A3 Method of use of five and fifteen carbon fatty acids
06/02/2005WO2004098500A3 CARBACEPHEM ss-LACTAM ANTIBIOTICS
06/02/2005WO2004097002A3 SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
06/02/2005WO2004096143A3 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
06/02/2005WO2004096136A3 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
06/02/2005WO2004094372A3 Compounds useful as serine protease inhibitors
06/02/2005WO2004092384A3 Means and methods for diagnosing and treating affective disorders
06/02/2005WO2004087098A3 Preserved ophthalmic compositions
06/02/2005WO2004074247A3 A1 adenosine receptor antagonists
06/02/2005WO2004066923A3 Compositions and methods for improving recovery after general anesthesia
06/02/2005WO2004063150A3 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process
06/02/2005WO2004043992A3 Imaging protein-protein interactions in living subjects
06/02/2005WO2004034975A3 Sustained release profile modification
06/02/2005WO2004033440A8 Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
06/02/2005WO2003075847A3 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
06/02/2005WO2003070823A9 Conjugates comprising a biodegradable polymer and uses therefor
06/02/2005US20050120398 Animal model for HCV infection
06/02/2005US20050119598 High citrate dialysate and uses thereof
06/02/2005US20050119552 Methods and systems for assessing biological material using optical detection techniques
06/02/2005US20050119503 Reacting a solid from an aqueous alkaline solution of gagapentin hydrochloride with sulfuric acid; neutralizing with inorganic bases; dissolving the solid in protic solvent and isolating; salts removed by filtration/distillation; adding another solvent and isolating; simplification; industrial scale
06/02/2005US20050119502 (Dialkylamino, morpholino, or imidazolyl)-alkoxyphenolic derivatives as drug delivery agents; improved bioavailability for oral administration
06/02/2005US20050119495 For use as catalysts in asymmetric reactions, such as, hydrogenation, hydride transfer, allylic alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation
06/02/2005US20050119492 Industrial scale acylation of 2-[1-(ethoxycarbonyl)butylamino]propionic acid with a carbonic acid derivative, activation with thionyl chloride, amidation with octahydroindol-2(S)-carboxylic acid, salt formation with tert-butylamine; hypotensive agents; angiotensin I-converting enzyme (ACE) inhibitor
06/02/2005US20050119489 Antidiabetic, anorexigenic, hypotensive, and anticholesterol agents that are synergistically combined with other active agents; obesity, premenstrual tension, hyperlipidemia, myocardial infarction and skin disorders
06/02/2005US20050119484 Mitotic kinesin inhibitors
06/02/2005US20050119482 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
06/02/2005US20050119461 Which have affinity for oxazoline compounds; for treatment of glaucoma, dementia, mood disturbances, degenerative conditions, and neurodegenerative diseases
06/02/2005US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics
06/02/2005US20050119453 Method of removing transition metals
06/02/2005US20050119352 Administration of a cell cycle checkpoint activator eg beta -lapachone or its derivative combined with an oncogenic kinase modulator eg imatinib
06/02/2005US20050119351 By adding hydrogen chloride to solution of sertraline free amine in a ketone
06/02/2005US20050119350 Treatment of effect of chemicals with their ultradilute stereoisomers
06/02/2005US20050119349 Process for chlorinating tertiary alcohols
06/02/2005US20050119348 arylguanidine derivatives, for example N-[4-(2,3-bis-Bocguanidino)benzyl]2-(benzyl-oxycarbonyl)-2-phenylaceataride, N-(4-guanidinobenzyl) 2-(benzyloxycarbonyl)-2-phenylacetamide hydrochloride; antimetastasis agents
06/02/2005US20050119345 2-Amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; effective for treating and preventing psychiatric disorders such as schizophrenia, anxiety, bipolar disorder and epilepsy, neurological diseases such as drug dependence, Alzheimer's disease, Huntington's chorea
06/02/2005US20050119344 Based on the different degree of protection that ensure the blood-vessels of the healthy and of the tumor tissue against the influence of blood-coagulation enhancing substances; formic (methane) acid; antiseptic and bactericide
06/02/2005US20050119343 Crystalline form; inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase; for oral administration
06/02/2005US20050119340 Reversed cubic phase or reversed hexagonal phase liquid crystal; provide sustained action and/or reduced dosage requirements; bupivacaine
06/02/2005US20050119338 Combination of cytochome p450 dependent protease inhibitors
06/02/2005US20050119337 Methods of application of Schisandrin B in the preparation of anticancer medications
06/02/2005US20050119336 Synthesis of derivatives of ginkgolide C
06/02/2005US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor
06/02/2005US20050119331 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
06/02/2005US20050119330 Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
06/02/2005US20050119327 1-benzyl-5-[(3-methylphenyl)amino]-3-phenyl-1H-indole-2-carboxylic acid; plasminogen activator inhibitor (PAI-1) inhibitor; fibrinolytic system disorder; atrial fibrillation, pulmonary and renal fibrosis, Alzheimer's disease; anticarcinogenic, antiischemic, anticoagulant, antidiabetic
06/02/2005US20050119326 Substituted aryloximes
1 ... 4667 4668 4669 4670 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 ... 7860